<DOC>
	<DOCNO>NCT01357993</DOCNO>
	<brief_summary>The main purpose study evaluate long-term safety tolerability JNS001 18 72 mg per day adult Attention-Deficit/Hyperactivity Disorder ( ADHD ) .</brief_summary>
	<brief_title>A Long-Term Study Safety JNS001 Adults With Attention-Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>This multicenter , open-label ( people involve know identity intervention ) , dose-titration ( adjust dose drug optimal result reach ) , long-term safety study adult patient diagnosis ADHD . The study consist Long-term phase ( 4-week titration period 44-week maintenance period ) 1-week Post-study phase . The 4 week-titration period find individualized dose patient regardless treatment precede study ( JNS001-JPN-A01 ) . Patients titrate start dose 18 mg/day 7 day , continue weekly ( +/- 2 day ) increment 9 18 mg individualize dose achieve . The titration period follow 44-week maintenance period combine 48-week ( 1-year ) treatment duration titration period . During maintenance period , dose adjust 18 72 mg depend patient ' symptom . In post-study phase , safety information collect last dose study treatment premature discontinuation . The study drug administer water daily morning dose 18 mg , 27 mg , 36 mg , 45 mg , 54 mg , 63 mg , 72 mg per day . The study treatment period 48 week ( titration period 4 week maintenance period 44 week ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Patients ( legallyacceptable representative patient 18 19 year old ) must sign Informed Consent Form ( ICF ) indicate understand purpose procedure require study willing participate study Patients complete precede study ( JNS001JPNA01 ) , consider appropriate continue JNS001 treatment extension study investigator subinvestigator Women childbearing potential must negative urine pregnancy test final assessment precede study . If sexually active , continue use effective method birth control throughout study Men must agree use doublebarrier method birth control donate sperm study 90 day receive last dose study drug . Patients report AEs would prevent transfer study precede study ( JNS001JPNA01 ) Patients judge ineligible patient study investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Methylphenidate hydrochloride</keyword>
	<keyword>Concerta</keyword>
	<keyword>Adults</keyword>
	<keyword>Attention-Deficit / Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Long term safety</keyword>
</DOC>